Cognitive impairment due to vascular disease
5-10 mg PO TID
Take with food
Increases cerebral blood flow and metabolism, anticonvulsation, cognition enhancement, neuroprotection, antioxidation, cerebral vasodilation
Some clinical studies show prophylactic effects in ischemic stroke & cognitive improvement
Sold as a legal pharmaceutical product in Japan, Europe, & Mexico
Not beneficial in Alzheimer's disease
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
Prolonged use: slight reductions in both systolic & diastolic blood pressure & blood glucose
Hypersensitivity to vinpocetine or other vinca alkaloids
Pts in incomplete homeostasis after cerebral haemorrhage
<18 years old
Hemophilia, heart problems or low blood pressure
Monitor INR in patients on warfarin
Pregnancy & Lactation
Pregnancy Category: avoid
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Peak Plasma Time: 1-1.5 hr
Half-Life, elimination: 1-2 hr
Absorption: 60% with food, 7% without
Metabolism: extensively to inactive apovincaminic acid in liver
Mechanism of Action
Shown to inhibit cGMP phosphodiesterase that has may result in increased cerebral blood flow
Reported to have calcium-channel blocker, voltage-gated sodium channel blocker, & acetylcholine release activities